Skip Navigation

A Phase I, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma Pro00039777

Brief Summary

Multiple Myeloma

Study Type:

III Identifier:

Study #:

Start Date:
Apr 19, 2020

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT04091126

View Complete Trial Details & Eligibility at